Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort

Lupus

Volumn 9, Issue 3, 2000, Pages 170-175

  Petri, M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Homocysteine; Systemic lupus erythematosus

Indexed keywords

HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY; PREDNISONE;

AGE; ANGINA PECTORIS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; GENDER; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0034109090     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828226     Document Type: Review

References (42)

1. Urowitz MB, Bookman AAM, Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
2. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med 1975; 58: 243-264.
3. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
5. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validations of the Systemic Lupus International Collaborating Clinics/American College Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
6. Petri M, Rheinschmidt M, Whiting-O'Keefe Q et al. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody. Ann Int Med 1987; 106: 524-531.
7. Petri M, Nelson L, Weimer F et al. The automated modified Russell viper venom time test for the lupus anticoagulant. J Rheumatol 1991; 18: 1823-1825.
8. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-519.
9. Petri M, Lakatta C, Magder L, Goldman DW. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254-259.
10. Petri M. Hydroxychloroquine used in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996: 5(Suppl. 1): S16-22.
11. Petri M. Hydroxychloroquine: past, present, future [editorial]. Lupus 1998 7: 65-67.
12. Petri M, Roubenoff R, Dallal GE et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-1124.
13. Petri M, Vu D, Omura A et al. Effectiveness of B-vitamin therapy in reducing plasma total homocysteine in patients with systemic lupus [abstract]. Arthritis Rheum 1998; 41(9 (Suppl.)): S241.
14. Alarcón-Segovia D, Delezé M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-374.
15. Hamsten A, Norberg R, Björkholm M et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113 -116.
16. Petri M. Epidemioloyg of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y (eds). The Antiphospholipid Syndrome CRC Press: Boca Raton, FL 1996, 13-28.
17. 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573.
18. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191-193.
19. Petri M, Zonana-Nacach A, Barr S, Magder L. Damage in systemic lupus erythematosus is dependent on dose and mode of delivery of corticosteroid [abstract]. Arthritis Rheum 1999; 42(Suppl): S97.
20. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
21. Petri M, Hamper U. Frequency of atherosclerosis detected by carotid duplex in SLE [abstract]. Arthritis Rheum 1997; 40: No. 9 Suppl.: S219.
22. Petri M, Civelek C. Discordance of myocardial SPECT and carotid duplex in systemic lupus erythematosus (SLE). Arthritis Rheum 1998; 41: No. 9 Suppl.: S.
23. Manzi S, Meilahn EN. Raire JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145(5): 408-415.
24. Karsh J, Klippel JH, Balow JE, Decker JL. Mortality in lupus nephritis. Arthritis Rheum 1979; 22: 764-769.
25. Wallace DJ, Podell T, Weiner J et al. Systemic lupus erythematosus -survival patterns: experience with 609 patients. J Am Med Assoc 1981; 245: 934-938.
26. Rosner S, Ginzler EM, Diamond HS et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982; 25: 612-617.
27. Helve T. Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol 1985; 14: 43-46.
28. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55: 87-98.
29. Jonsson H, Hived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68: 141-150.
30. Shome GP, Sakauchi M, Yamane K et al. Ischemic heart disease in systemic lupus erythematosus. A retrospective study of 65 patients treated with prednisone. Japan J Med 1989; 28: 599-603.
31. Reveille JS, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33: 37-48.
32. Pistiner M, Wallace DJ, Nessim S et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Arthritis Rheum 1991; 21: 55-64.
33. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259-1264.
34. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Arthritis Rheum 1995; 38: 1492-1499.
35. Bidani AK, Roberts JL, Schwartz M, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 1980; 69: 849-858.
36. Godeau P, Guilleven L, Fechner J et al. Manifestations cardiques du lupus erythemateaux aigu dissemine. Nouv Presse Med 1981; 10: 2175-2178.
37. Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus: quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981; 70: 775-781.
38. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987; 14(Suppl 13): 223-226.
39. Hearth-Holmes M, Baethge BA, Broadwell L, Wolf RE. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol 1995; 22: 450-454.
40. Sturfelt G, Eskilsson J, Nived O et al. Cardiovascular disease in systemic lupus erythematosus: a study of 75 patients from a defined population. Medicine 1992; 71: 216-223.
41. Hospenpud JD, Montanaro A, Hart MV et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984; 77: 286-292.
42. Leung W-H, Wong K-L, Lau C-P et al. Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross-sectional and Doppler echocardiographic study. Int J Cardiol 1990; 27: 367-375.